ceritinib
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
Conditions
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
— → —
NCT ID
NCT05100134About ceritinib
ceritinib is a pre-clinical stage product being developed by Novartis for Anaplastic Lymphoma Kinase (ALK)- Positive Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05100134. Target conditions include Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05100134 | Pre-clinical | Active |
| NCT02584933 | Approved | Active |
| NCT02638909 | Phase 2 | Terminated |
| NCT02513667 | Phase 2 | Terminated |
| NCT02289144 | Phase 2 | Withdrawn |
| NCT02343679 | Phase 2 | Withdrawn |
| NCT02299505 | Phase 1 | Completed |
| NCT02336451 | Phase 2 | Completed |
| NCT02186821 | Phase 2 | Terminated |
| NCT01742286 | Phase 1 | Completed |
Competing Products
20 competing products in Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |
| Lenvatinib + Nivolumab | Ono Pharmaceutical | Phase 2 | 52 |
| durvalumab + tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| LDK378 + AUY922 | Novartis | Phase 1 | 33 |
| LDK378 | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 52 |
| Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim | Novartis | Phase 1 | 33 |
| dabrafenib/trametinib | Novartis | Phase 2 | 52 |
| Trametinib + Paclitaxel | Novartis | Phase 1 | 33 |
| Alectinib + Crizotinib | Roche | Phase 3 | 77 |
| Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Crizotinib (PF-02341066) | Pfizer | Phase 2 | 51 |
| Lorlatinib | Pfizer | Phase 2 | 51 |
| Crizotinib | Pfizer | Phase 1/2 | 40 |
| Cemiplimab + XL092 | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Etirinotecan pegol | Nektar Therapeutics | Phase 2 | 47 |
| Bevacizumab | Novocure | Phase 2 | 47 |